Cardiovascular studies and gliflozins

Česká verzia

Authors: Jindřich Špinar ¹; Lenka Špinarová ²; Jiří Vítovec ²
Authors place of work: Fyziologický ústav LF MU, Brno ¹; I. interní kardioangiologická klinika, LF MU a FN u sv. Anny v Brně ²
Published in the journal: Forum Diab 2019; 8(3): 200-207
Category:

Summary

Diabetes mellitus type 2 is an epidemy of the 21st century. The Food and Drug Administration (FDA) announced that cardiovascular safety after peroral antidiabetics is a more important goal than the lowering of glycemia and this was the beginning of a large program with antidiabetics and cardiovascular goals. The guidelines for heart failure accent the positive effect of SGLT2 inhibitors with the indication IIa in 2016. Two important European documents on antidiabetics and cardiovascular outcomes called position statement were published by the European Society of Cardiology in 2018, especially on the effect of heart failure. “An expert concensus meeting report of the HFA of the ESC,” will be published in autumn 2019 and the first part is about SGLT2 – gliflozins. Clinical study DAPA –HF was presented on ESC congress in september 2019 and showed positive effect of dapagliflozin on heart failure.

Keywords:

diabetes mellitus – gliflozins – heart failure – mortality

Zdroje

Bartášková D, Kožnarová R, Kvapil M. Analýza farmakoekonomických aspektů léčby diabetes mellitus v České republice. Remedia 2004; 14(4): 377–384
Brož J, Honěk P, Dušek L, Pavlík T, Kvapil M. [The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003–2013 and came closer to the population average]. Vnitr Lek 2015; 61(11 Suppl 3): 3S14–3S20.
Kvapil M, Benešová K, Jarkovský J et al. Nejčastější příčiny hospitalizace a úmrtí u pacientů s diabetem – výsledky českého diabetologického registru. Kardiol Rev Int Med 2019, 21(1): 5–6.
Niessner A, Tamargo J, Koller L et al. Non-insulin antidabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2018; 39(24): 2274–2281. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx625>.
Seferovic PE, Petrie MC, Filipatos GS et al. [Working Group on Cardiovascular Pharmacotherapy].Type 2 diabetes mellitus and Heart failure: a position paper of the European Society of Cardiology. Eur Heart J 2018; 20(5): 853–872. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1170>.
Seferovic PM, Ponikowski P, Anker SD et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1531>.
Wiviott SD, Raz M, Bonaca O et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.
Špinar J, Špinarová L, Vítovec J. Studie DECLARE potvrdila příznivý efekt dapagliflozinu. Kardiol Rev Int Med 2019; 21(1): 7–12.
Zelniker TA, Wiviot SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trial. Lancet 2019; 393(10166): 31–39. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32590-X>.
Packer M. Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. Diabetes Obes Metab 2018; 20(7): 1766–1769. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13265>.
Vítovec J, Špinar J, Špinarová L. Diabetes mellitus a kardiovaskulární onemocnění. Kardiol Rev Int Med 2018; 20(2): 118–122.
Vítovec J, Špinar J, Špinarová L. Glifloziny – naděje pro diabetiky s kardiovaskulárním onemocněním. Acta Medicinae 2018; 2–3: 71–77.
Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 2016; 39(7): 1115–1122. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–0542>.
Neal B, Perkovic P, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.
Wanner C, Lachin JM, Inzucchi SE et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018; 137(2): 119–129. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028268>.
Verma S, Juni P, Mazer CD. Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet 2019; 393(10166): 3–5. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32824–1.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37(27): 2129–2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>. Erratum in Erratum. [Eur Heart J. 2018]
Špinar J, Hradec J, Špinarová L et al. Souhrn Doporučených postupů ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání z roku 2016. Připraven Českou kardiologickou společností. Cor Vasa 2016; 58(5):e530-e568. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crvasa.2016.09.004>.
Cosentino F, Grant JP, Aboyans V et al 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019; pii: ehz486. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.
Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280(1): F10–8. Dostupné z DOI: <http://doi 10.1152/ajprenal.2001.280.1.F10>.
Lee YJ, Lee YJ, Han HJ et al. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007; 106(Suppl): S27–S35. Dostupné z DOI: <http://doi 10.1038/sj.ki.5002383>.
Hummel CS, Lu C, Loo DD et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 2011; 300(1): C14–21. Dostupné z DOI: <http://doi 10.1152/ajpcell.00388.2010>.